Alistair Duncan, B.Sc., C.A.       Co-founder of the Company in 2008 Mr. Duncan serves as President and Chief Executive Officer (CEO) of the Company.  From 2009 to present, Mr Duncan has also served as the interim Chief Financial Officer for Agrisoma Biosciences Inc., a company building a high performance crop seeds business for the development of new genetically modified crops for renewable fuels. From 1998 to 2008, Mr. Duncan was President and CEO of Chromos Molecular Systems Inc., where he was also a founder and Director. Prior to that, he was a Principal with the Ernst & Young Corporate Finance and International Life Sciences Group where he provided high technology and life sciences companies with corporate advisory services in strategic planning, valuations, financing, divestitures, and mergers and acquisitions. Currently, Mr. Duncan also serves as a director on the board of Metro Vancouver Properties Corp.  Mr. Duncan is a member of the Institute of Chartered Accountants of British Columbia and holds a B.Sc. in Biochemistry from the University of British Columbia.

 

Taryn Boivin, Ph.D.      Dr. Boivin serves as Senior Vice President, Scientific Affairs & Operations. Her experience spans over 20 years in both multi-national and start-up pharmaceutical operations and instrument technology companies. Dr. Boivin was most recently VP, Pharmaceutical Sciences & Manufacturing and Corporate Officer at Cardiome Pharma Corporation. Dr. Boivin led the CMC development of Vernaklant, which resulted in a significant global partnering deal with Merck and eventual commercialization. Her experience also includes 11 years with GSK (then Glaxo) in several positions including Director, Product Development. She was involved in growing the Canadian operation into a world-class research and development facility for worldwide product development. Dr. Boivin led sales, service, and related marketing functions at Agilent Technologies (formerly Hewlett Packard) as Business Manager, Central and Western Canada, was Principal of Level 10 BioSciences Ltd., and was VP, Pharmaceutical Development at Oncogenex Technologies Inc.. Dr. Boivin holds a Ph.D. in Chemistry (Organic) from the University of Alberta and a BSc. (Chemistry) from Simon Fraser University.

 

Mr. Jeff Charpentier C.A.      Prior to joining viDA as Chief Financial Officer (CFO) in October 2011, Mr. Charpentier served as a financial advisor to the Company through its start up phase. Over the course of the past fifteen years, Mr. Charpentier has held a series of senior financial roles at several public companies in the pharmaceutical and technology sectors where he led multiple equity financings raising in excess of $125 million and concluded a number of corporate partnering/product sale transactions. Since October 2010, Mr. Charpentier has served as CFO to Lifebank Corp. on a part-time basis. Prior to joining Lifebank, Mr. Charpentier previously served as VP Finance & CFO for each of Inex Pharmaceuticals Corporation, Chromos Molecular Systems Inc., and Lignol Energy Corporation and as Director of Finance with Sierra Wireless Inc. Mr. Charpentier has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Institute of Chartered Accountants of British Columbia.

 

David Granville, Ph.D.       Co-founder and scientific founder of the Company in 2008, Dr. Granville serves as the Company’s Chief Scientific Officer and is an Associate Professor at the Providence Heart + Lung Institute at St. Paul’s Hospital, University of British Columbia (UBC). Dr. Granville completed his Ph.D. at UBC and post-doctoral training at the Scripps Research Institute (La Jolla, CA). He worked in preclinical pharmacology at QLT Inc. from 1994-2000. Dr. Granville was recruited to UBC in 2003 as a Tier II Canada Research Chair and Michael Smith Foundation for Health Research Scholar. Since then, Dr. Granville has received numerous awards for his scholarly and research achievements including a Canada Top 40 Under 40™ award, 2010 Business in Vancouver Forty Under 40 award, 2006 UBC Outstanding Young Alumnus Award, 2007 Simon Fraser University Academic Alumnus Award, 2008 Canadian Academy of Pathology Scientist award and was a finalist for the prestigious 2007 Louis and Arnold Katz Basic Science Prize at the American Heart Association Scientific Sessions.